Taiho Pharmaceutical to expand ADC portfolio with Araris Biotech acquisition

Taiho Pharmaceutical is acquiring Araris Biotech for $1.14 billion, strengthening its ADC oncology pipeline. Discover how this deal is shaping the future of cancer treatment. Read More